Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland.

Human papillomavirus (HPV) type 16 is the major cause of cervical carcinoma, the incidence of which is decreasing in western countries. In Finland the incidence is, however, increasing in women aged <40 years, but possible underlying changes in HPV-16 epidemiology are unknown. To assess incidence trends of HPV infections, paired sera from a random sample of 8000 women with two pregnancies/sera within 5 years, taken from the serum bank of the Finnish Maternity Cohort (1983-98), were analysed for HPV-6, -11 and -16 antibodies. For 23-31-year-old women, HPV-16 incidence increased over the period 1983-97. HPV-16 seroprevalence increased from 17% in 1983-85 to 24% in 1995-97, but HPV-6 and HPV-11 prevalence was stable at 9-12% throughout the study period. Epidemic spread of the oncogenic HPV-16, but not the non-oncogenic HPV-types, throughout the 1980s and 1990s preceded an increase in the incidence of cervical carcinoma in fertile-aged Finnish women.

[1]  E. Haavio-Mannila,et al.  Trends in sexual life : Measured by national sex surveys in Finland in 1971, 1992 and 1999, and a comparison to a sex survey in St. Petersburg in 1996 , 2001 .

[2]  P. Saikku,et al.  Seropositivity to Multiple Sexually Transmitted Infections Is Not Common , 2000, Sexually transmitted diseases.

[3]  D M Parkin,et al.  International trends in incidence of cervical cancer: II. Squamous‐cell carcinoma , 2000, International journal of cancer.

[4]  M. Lehtinen,et al.  Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination , 2000, Sexually transmitted infections.

[5]  L. Wen,et al.  Risk factors for the acquisition of genital warts: are condoms protective? , 1999, Sexually transmitted infections.

[6]  M. Hakama,et al.  Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963–1995: Recent increase in cervical cancer incidence , 1999, International journal of cancer.

[7]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[8]  K Sigurdsson,et al.  The Icelandic and Nordic cervical screening programs, Trends in incidence and mortality rates through 1995 , 1999, Acta obstetricia et gynecologica Scandinavica.

[9]  M. Lehtinen,et al.  Stability over time of serum antibody levels to human papillomavirus type 16. , 1998, The Journal of infectious diseases.

[10]  J. Dillner,et al.  Trends in seroprevalence of human papillomavirus type 16 among pregnant women in Stockholm, Sweden, during 1969–1989 , 1998, International journal of cancer.

[11]  N. Kiviat,et al.  The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. , 1996, The Journal of infectious diseases.

[12]  M. Lehtinen,et al.  Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. , 1996, The Journal of infectious diseases.

[13]  R. Marks,et al.  Squamous cell carcinoma , 1996, The Lancet.

[14]  R. Peto,et al.  Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study , 1996, BMJ.

[15]  P. Knekt.  Serum alpha-tocopherol and the risk of cancer , 1988 .